The Day After: Tracking the rebirth of the US consumer with real-time transactional data as lockdowns gradually end; no evidence yet of material second waves of COVID infection, either in the US or around the world; Vaccine round-up (Moderna, Oxford, Sinovac) & anticoagulants

There are a lot of issues I’ve been discussing with clients on Zoom calls, which I was going to write about this week: a recent shift in swing state polls in favor of Vice President Biden, rising probabilities of a Democratic sweep and possible market consequences; the risk of deflationary and inflationary shocks; household and corporate debt burdens after the pandemic; and what will happen to the Federal debt.

I will save that for next time. Instead, here’s our new analysis on the US consumer based on select internal Chase transaction data1. We’ve been posting a chart on our virus portal showing indicators that are rising from low levels (gasoline demand, rail traffic for consumer goods, hotel occupancy, mortgage applications, etc). However, this is national data that includes states that are locked down, states that already reopened, states that reopened in some areas only, etc. As a result, national data is not the best way to assess what the US might look like once the virus recedes and lockdowns end2.

Our new tools differentiate between states based on virus severity and policy characteristics, and include real-time transactional data through May 11, 2020. Over time, these tools can help highlight secular shifts in consumer behavior that may last after the pandemic is over, with implications for retailing, commercial real estate, e-commerce, etc.

Tracking the rebirth of the US consumer

On a national level, consumer spending in our credit and debit card data set3 is down 15% vs 2019 (first chart). However, this aggregation includes a lot of e-commerce. When narrowing the focus to consumer transactions that took place with “cards present”, the y/y decline is much larger (second chart).

---

1 This report uses rigorous security protocols for selected data sourced from Chase credit and debit card transactions to ensure all information is kept confidential and secure. All selected data is highly aggregated and all unique identifiable information, including names, account numbers, addresses, dates of birth, and Social Security Numbers, is removed from the data before the report’s author receives it.

2 To be clear, the US is reopening despite one of the highest infection rates per mm people in the world, which is the basis of my “Logan’s Run” analogy last week; see virus web portal sections 1 and 2.

3 Our data may or may not be representative of national consumer spending trends. While it is based on a large number of cardholders, we have not made any attempt to normalize the data for age, gender, income or other factor differences vs the national average.
For many reasons (housing, commercial real estate, transportation, etc), we’re interested in discretionary “social distancing spending” (SDS) as well. For our purposes, we define SDS as “card present” transactions for retail, lodging, restaurants, amusement parks, tourist attractions, theaters, night clubs and other recreational services. In other words, spending that requires people to go someplace and not buy from home. For context, in our dataset, card-present SDS represented around one third of all consumer spending in 2019. The SDS decline this year is even sharper than the decline in total spending, since the latter includes food, gasoline, recurring payments and other non-discretionary items.

However, the line chart above includes a mix of states with different lockdown policies and infection rates. How quickly might SDS recover once lockdowns end and when infections fall? That’s what we attempt to analyze next. The chart below shows the change in SDS as a function of each state’s current reopening status. As you might expect, states that never had a lockdown, and the states that have already reopened by now, are seeing faster SDS recoveries while the others are still stuck in neutral. As an investor, what matters more to me at this stage is the pace of SDS recovery, rather than the y/y level.
Another way to understand the impact of the virus on spending and what might happen when it eventually fades: how is SDS faring in states with lower infection and mortality rates? The next chart looks at SDS as a function of infections to date, which we rank in quartiles. As you might expect, states with the lowest quartile of infections per capita are experiencing faster recoveries in SDS. The same holds true for SDS relative to deaths per capita, and relative to recent infection trends.

Credit and debit card spending trends according to quartile of total COVID infections per mm people
Social distancing categories, card present transactions only
Spending change 2020 vs 2019, 7 day smoothing

The next chart shows oil/gasoline spending, for which the pace of recovery is more muted.

Credit and debit card spending trends according to quartile of total COVID infections per mm people
Oil only, all transactions
Spending change 2020 vs 2019, 7 day smoothing
What about retail spending based on e-commerce? It’s booming, even in more open states.

Credit and debit card spending trends according to current state reopening status
Retail only, ecommerce transactions only
Spending change 2020 vs 2019, 7 day smoothing

The final two charts compare e-commerce and “card present” transactions for retail only, and then for all spending categories in our dataset. Lingering consumer preferences for e-commerce after the pandemic is over may be one of its more lasting legacies, with implications for a wide range of sectors and industries.
Searching for second infection waves: nothing found, yet

What does a second infection wave look like? We scanned for countries whose infection rates (a) dropped sharply from prior higher levels, (b) appeared to be contained, and then (c) rose again. We only found three countries that came close to meeting this definition: Greece, Lebanon and South Korea (left chart). But to put things in context, as shown on the right, these countries’ infection rates pale in comparison to infection levels elsewhere. So, despite various stages of reopening taking place across Asia and Europe, we are not finding reported evidence yet of material second waves of infection.

The same holds true for the US states, to which we’re applying the same second wave litmus tests. The only state that showed up so far is Montana, whose stay-at-home order expired on April 26, with restaurants and bars reopening on May 4. However, at 2 cases per mm people, Montana has a miniscule infection rate compared to states like Washington, which itself is below the median US state. The bigger problem for the US is not second waves but how stubborn the first wave has been: Washington was one of the earliest outbreak zones, and its COVID infection rate hasn’t really improved in the last month.
Moderna, Oxford, SinoVac and anticoagulants (blood thinners)

- **Moderna** released interim results from its Phase I mRNA vaccine trial. Of 45 vaccine recipients, immunogenicity (the level of immune response) increased according to dosage in all of them, which is good news. For most patients, antibody efficacy results were not available yet (i.e., whether or not antibodies were “neutralizing” with respect to the virus). However, of 8 patients whose detailed results were available, all had neutralizing antibodies in amounts similar to that seen in recovered patient blood samples, which is more good news. To be clear, **neutralizing antibodies are the goal of any vaccine, but they must also be generated in sufficient amounts to overcome the virus; that’s something that can only be determined in Phase II/III**. Moderna reported no “serious” adverse reactions among the vaccine recipients, and also released preliminary information on an animal trial using a mouse model of disease, which although limited, was also encouraging. “Limited but very promising” is the way my sources tended to assess the results.

- **Oxford** released a preliminary research paper stating that its vaccine had successfully generated antibodies in rhesus monkeys within 28 days, and that no lung damage or disease was observed in vaccinated monkeys. However, Oxford did acknowledge that the virus was still actively replicating in the noses of the monkeys. **This latter fact was the basis for some swift disagreement regarding the progress Oxford is making**. American biotech pioneer William Haseltine (former Harvard Medical School professor known for his groundbreaking work on HIV/AIDS and the human genome) wrote⁴ that there was no major difference in the viral load measured across treated and placebo monkey groups. Furthermore, Haseltine considered the level of antibodies reported by Oxford to be very low compared to typical vaccines. However, others have noted that the vaccinated monkeys did not suffer from viral pneumonia, while the 2/3 of the placebo group did. So, some red flags here that are worth watching as Oxford moves to human clinical trials.

- **Sinovac** also announced results from its monkey vaccine trials. For the highest-dosed monkeys, no viral DNA was found, and the vaccine apparently provided “sterilizing” immunity (i.e., the virus would have no ability to replicate if enough people were vaccinated, since enough neutralizing antibodies are created⁵). The vaccine dosage and viral load infection levels were different across Sinovac and Oxford monkey trials (the latter used very high viral loads), so they are not that easy to compare. Results from human trials will be the next important disclosure to evaluate from both of their vaccine efforts.

- A May report in the *Journal of the American College of Cardiology* analyzed medical records of 2,773 COVID-19 patients in NYC hospitals. The study was initiated after doctors realized that COVID can result in life-threatening blood clots. Notable findings: survival rates for intubated patients treated with anticoagulants were 71% compared to 37% for who did not. This is not an anti-viral treatment, but is another example of pharmaceutical interventions that can reduce mortality.

---

⁴ “Did the Oxford COVID vaccine work in monkeys? Not really”, William Haseltine, Forbes, May 16, 2020
⁵ “Criticisms of the Oxford coronavirus vaccine”, Derek Lowe, May 18, 2020
Purpose of This Material: This material is for information purposes only. The views, opinions, estimates and strategies expressed herein constitute Michael Cremonte’s judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

GENERAL RISKS & CONSIDERATIONS
Any views, strategies or products discussed in this material may not be appropriate for all individuals and are subject to risks. Investors may get back less than they invested, and past performance is not a reliable indicator of future results. Asset allocation / diversification does not guarantee a profit or protect against loss. Nothing in this material should be relied upon in isolation for the purpose of making an investment decision. You are urged to consider carefully whether the services, products, asset classes (e.g. equities, fixed income, alternative investments, commodities, etc.) or strategies discussed are suitable to your needs. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan representative.

NON-RELIANCE
Certain information contained in this material is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this material. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this material, which are provided for illustration/reference purposes only. The views, opinions, estimates and strategies expressed in this material constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in this material in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and this material should not be regarded as a research report. Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events.

Nothing in this document shall be construed as giving rise to any duty of care owed to, or advisory relationship with, you or any third party. Nothing in this document shall be regarded as an offer, solicitation, recommendation or advice (whether financial, accounting, legal, tax or other) given by J.P. Morgan and/or its officers or employees, irrespective of whether or not such communication was given at your request.

J.P. Morgan and its affiliates and employees do not provide tax, legal or accounting advice. You should consult your own tax, legal and accounting advisors before engaging in any financial transactions.

LEGAL ENTITY, BRAND & REGULATORY INFORMATION
In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank-managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPM”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPM and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

In Luxembourg, this material is issued by J.P. Morgan Bank Luxembourg S.A. (JPMLB), with registered office at European Bank and Business Centre, 6 route de Treves, L-2633, Senningerberg, Luxembourg. R.C.S Luxembourg B10.958. Authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is authorized as a credit institution in accordance with the Law of 5th April 1993. In the United Kingdom, this material is issued by J.P. Morgan Bank Luxembourg S.A.– London Branch. Prior to Brexit (Brexit meaning that the UK leaves the European Union under Article 50 of the Treaty on European Union, or, if later, loses its ability to passport financial services between the UK and the remainder of the EEA), J.P. Morgan Bank Luxembourg S.A.– London Branch is subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from us on request. In the event of Brexit, in the UK, J.P. Morgan Bank Luxembourg S.A.– London Branch is authorised by the Prudential Regulation Authority, subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. In Spain, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Sucursal en España, with registered office at Paseo de la Castellana, 31, 28046 Madrid, Spain. J.P. Morgan Bank Luxembourg S.A., Sucursal en España is registered under number 1516 within the administrative registry of the Bank of Spain and supervised by the Spanish Securities Market Commission (CNMV). In Germany, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Frankfurt Branch, registered office at Taunustor 1 (TaunusTurm), 60310 Frankfurt, Germany, jointly supervised by the Commission de Surveillance du Secteur Financier (CSSF) and the European Central Bank (ECB), and in certain areas also supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). In Italy, this material is distributed by J.P. Morgan Bank Luxembourg S.A– Milan Branch, registered office at Via Catena Adalberto 4, Milan 20121, Italy and regulated by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB). In the Netherlands, this material is distributed by J.P. Morgan Bank Luxembourg S.A. Amsterdam Branch, with registered office at World Trade Centre, Tower B, Strawinskylaan 1135, 1077 XX, Amsterdam, The Netherlands. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF in Luxembourg. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised and supervised by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In Denmark, this material is distributed by J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A.is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finanstilsynet (Danish FSA) and registered with Finanstilsynet as a branch of J.P. Morgan Bank Luxembourg S.A. under code 29009. In Sweden, this material is distributed by J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial, with registered office at Hammadsgatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A., Stockholm Branch is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A., Stockholm Branch is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden.

Purpose: This material is for information purposes only. The views, opinions, estimates and strategies expressed herein constitute Michael Cremonte’s judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.
In Hong Kong, this material is distributed by JPMCB, Hong Kong branch. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, this material is distributed by JPMCB, Singapore branch. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Banking and custody services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. This advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder’s liability is limited.

In Switzerland, this material is distributed by JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to “wholesale clients” only. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future. JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority.

JPMS is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPMS), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. JPMS is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws under the Corporations Act 2001 (Cth) (Act). Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future. This material has not been prepared specifically for Australian investors. It:
• may contain references to dollar amounts which are not Australian dollars;
• may contain financial information which is not prepared in accordance with Australian law or practices;
• may not address risks associated with investment in foreign currency denominated investments; and
• does not address Australian tax issues.

With respect to countries in Latin America, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund’s securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission–CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

© 2020 JPMorgan Chase & Co. All rights reserved.